Targeting MuRF1 by small molecules in a HFpEF rat model improves myocardial diastolic function and skeletal muscle contractility

BACKGROUND: About half of heart failure (HF) patients, while having preserved left ventricular function, suffer from diastolic dysfunction (so‐called HFpEF). No specific therapeutics are available for HFpEF in contrast to HF where reduced ejection fractions (HFrEF) can be treated pharmacologically....

Descripción completa

Detalles Bibliográficos
Autores principales: Adams, Volker, Schauer, Antje, Augstein, Antje, Kirchhoff, Virginia, Draskowski, Runa, Jannasch, Anett, Goto, Keita, Lyall, Gemma, Männel, Anita, Barthel, Peggy, Mangner, Norman, Winzer, Ephraim B., Linke, Axel, Labeit, Siegfried
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178400/
https://www.ncbi.nlm.nih.gov/pubmed/35301823
http://dx.doi.org/10.1002/jcsm.12968

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178400/
https://www.ncbi.nlm.nih.gov/pubmed/35301823
http://dx.doi.org/10.1002/jcsm.12968

Ejemplares similares